DCC0545 |
Alkyne-a-dsbso
Featured
|
Novel Enrichable and MS-Cleavable Cross-linker to Define Protein-Protein Interactions by Mass Spectrometry |
|
DCC0546 |
Gsk1360707f |
Potent and selective triple reuptake inhibitor |
|
DCC0547 |
Allo-i1e-isoindoline |
Irreversible and selective dipeptidyl peptidase 8 and 9 (DPP-8/9) inhibitor |
|
DCC0548 |
Allo-ile-isoindoline Hcl |
Irreversible and selective dipeptidyl peptidase 8 and 9 (DPP-8/9) inhibitor |
|
DCC0549 |
Alloswitch-1 |
Novel allosteric modulator to control endogenous G protein-coupled receptors with light |
|
DCC0550 |
Alloxan Hydrate [3237-50-1] |
Natural chemical suppressor of mlo-mediated resistance in monocotyledonous barley (Hordeum vulgare) and dicotyledonous Arabidopsis thaliana |
|
DCC0551 |
Allylpyrocatechol |
Antioxidant, attenuating collagen-induced arthritis via attenuation of oxidative stress secondary to modulation of the MAPK, JAK/STAT, and Nrf2/HO-1 pathways |
|
DCC0552 |
Alpha7-pam-3ea |
Novel potent type I positive allosteric modulator (PAM) of human α7 nAChR |
|
DCC0553 |
Alpha-amplexichromanol |
Highly potent, orally effective, and metabolically stable allosteric 5-LOX Inhibitor |
|
DCC0554 |
Alpha-br-tmc |
Novel JAK2/STAT5 inhibitor |
|
DCC0555 |
Alpha-cf3-tmc |
Novel inhibitor of JAK2 and STAT5 phosphorylation in response to interleukin-3 without altering STAT5 mobility in SDS-PAGE |
|
DCC0556 |
Alpha-ethylmescaline |
Psychedelic, an analog of mescaline |
|
DCC0557 |
Alpha-ketoamide-13b |
Novel potent inhibitor of the SARS-CoV-2 Mpro, revealing a pronounced lung tropism and suitability for administration by the inhalative route |
|
DCC0558 |
Alpha-lipoic Acid |
One of the most effective antioxidants, being involved in the cellular antioxidant system |
|
DCC0559 |
Alpha-methylserotonin Creatinine Sulfate |
Neurotransmitter; stimulating nicotinic receptors |
|
DCC0560 |
Alpha-ra-f |
Novel modulator of collagen synthesis and matrix metalloproteinases (MMPs) expression levels, boosting collagen synthesis and reducing MMPs expression levels in human fibroblasts without cytotoxicity |
|
DCC0561 |
Alpha-tocopherol Phosphate |
Prodrug of Vitamin E, modulating atherosclerotic and inflammatory events more efficiently than the unphosphorylated alpha-tocopherol |
|
DCC0562 |
Alrestatin Sodium |
Specific inhibitor of aldose reductase |
|
DCC0563 |
Als-i-41 |
Novel potent and selective oxytocin receptor antagonist |
|
DCC0564 |
Alsterpaullone, 2-cyanoethyl |
Novel selective dual inhibitor of Cdk1/cyclin B and GSK-3β |
|
DCC0565 |
Alvespimycin Hydrochloride |
Inhibitor of HSP90, leading to the degradation and depletion of its client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction |
|
DCC0566 |
Alvimopan |
Peripherally acting µ-opioid antagonist |
|
DCC0567 |
Alx Antagonist |
Novel lipoxin A4 receptor/formyl peptide receptor 2 (ALX/FPR2) antagonist |
|
DCC0568 |
Alx5406 |
Prodrug of ALX5407, a selective non-transportable inhibitor of the glycine transporter GlyT1 |
|
DCC0569 |
Alx-5670 |
Potent GlyT-2 antagonist |
|
DCC0570 |
Am-0687 |
Novel potent, selective, and orally bioavailable PI3Kdelta inhibitor |
|
DCC0571 |
Am10257 |
Novel Cannabinoid Receptor CB2 antagonist |
|
DCC0572 |
Am1336 |
The first covalent hCB2 antagonist/inverse agonist |
|
DCC0573 |
Am-1430 |
Novel potent, selective, and orally bioavailable PI3Kdelta inhibitor |
|
DCC0574 |
Am-3189 |
Novel GPR40 agonist with minimal CNS penetration, superior pharmacokinetic properties and in vivo efficacy comparable to AMG 837 |
|